PARKINTREAT 1 mg tablets
Always take PARKINTREAT exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.
If you take more PARKINTREAT than you should
If you think that you may have taken too many PARKINTREAT tablets, contact your doctor or pharmacist immediately. Take the PARKINTREAT carton with you to show the doctor or pharmacist.
If you forget to take PARKINTREAT
Do not take a double dose to make up for a forgotten dose. Take the next dose normally, when it is time to take it.
If you stop taking PARKINTREAT
Do not stop taking PARKINTREAT without first talking to your doctor. If you have any further questions on the use of this product, ask your doctor or pharmacist.
Do not take PARKINTREAT
if you are allergic (hypersensitive) to rasagiline or any of the other ingredients of PARKINTREAT.
if you have moderate or severe liver problems.
Do not take the following medicines while taking PARKINTREAT:
The use of PARKINTREAT together with the antidepressants containing fluoxetine or fluvoxamine should be avoided.
monoamine oxidase (MAO) inhibitors (selective or non-selective) (e.g. for treatment of depression or Parkinson’s disease, or used for any other indication), including medicinal and natural products without prescription e.g. St. John's Wort.
pethidine or meperidine ,tramadol, methadone ,propoxyphene , (strong pain killers).
dextromethorphan, or cyclobenzaprine
Coadministration with Antidepressants:
Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant. These adverse reactions are often described as “serotonin syndrome” which can result in death.
Ciprofloxacin and Other CYP1A2 Inhibitors:
patients taking concomitant ciprofloxacin or other CYP1A2 inhibitors should use 0.5 mg daily of PAKINTREAT
Patients with mild hepatic impairment should be given the dose of 0.5 mg/day. PAKINTREAT should not be used in patients with moderate or severe hepatic impairment.
Risk for Hypertensive Crisis and other adverse reactions associate d with nonselective inhibition of MAO Above The Recommended Doses
restriction is not ordinarily required with recommended doses of PAKINTREAT. However, certain foods ( e. g. , aged cheeses, such as Stilton cheese) may contain very high amounts ( i. e. , > 150 mg) of tyramine and could potentially cause a hypertensive “ cheese” reaction in patients taking PAKINTREAT even at the recommended dose due to mild increased sensitivity to tyramine. The selectivity for inhibiting MAO- B diminishes in a dose- related manner as the dose is progressively increased above the recommended daily dose.
Melanoma:Patients being treated with PAKINTREAT should be advised to have periodic skin examination that should be performed by appropriately qualified individuals (e.g., dermatologists).
Dyskinesia Due to Levodopa Treatment:
decreasing the dose of levodopa may ameliorate this side effect.
Lowering of Blood Pressure and Postural/Orthostatic Hypotension:
postural hypotension occurs most frequently in the first two months of rasagiline treatment and tends to decrease over time.
Elevation of Blood Pressure
Hallucinations / Psychotic-Like Behavior :
Patients should be cautioned of the possibility of developing hallucinations. Patients with a major psychotic disorder should ordinarily not be treated with PAKINTREAT because of the risk of exacerbating the psychosis.In addition, many treatments for psychosis that decrease in central dopaminergic tone may decrease the effectiveness of PAKINTREAT
Withdrawal-Emergent Hyperpyrexia and Confusion
A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central dopaminergic tone.
Impulse Control/ Compulsive Behaviors:
Patient s should inform their physician if they experience new or increased gambling urges, increased sexual urges, or other intense urges while taking rasagiline. Physicians should consider dose reduction or stopping the medication if a patient develops such urges while taking rasagiline
Taking other medicines
Please tell your doctor or pharmacy if you are taking or have recently taken any other medicines, including medicines obtained without prescription or if you are smoking or intend to stop smoking.
Ask your doctor for advice before taking any of the following medicines together with PARKINTREAT:
Certain antidepressants (selective serotonin reuptake inhibitors, selective serotonin-noradrenaline reuptake inhibitors, tricyclic or tetracyclic antidepressants) The use of PARKINTREAT together with the antidepressants containing fluoxetine or fluvoxamine should be avoided.
If you are starting treatment with PARKINTREAT, you should wait at least 5 weeks after stopping fluoxetine treatment. If you are starting treatment with fluoxetine or fluvoxamine, you should wait at least 14 days after stopping PARKINTREAT treatment.
Taking PARKINTREAT with food and drink
Pregnancy and breast-feeding
Keep out of the reach and sight of children. Keep at a temperature not exceeding 30 ͦ C
What PARKINTREAT contains
Each tablet contains:
What PARKINTREAT looks like and contents of the pack